PLK1 and neoplasm: Furthermore, the folate‐decorated nanoparticles that delivered RNP targeting PLK1 demonstrated significant gene disruption (47.1% gene deletion) and tumor growth inhibition in vivo.[181] In another study, sorafenib and CRISPR/Cas9 were codelivered using polyamidoamine–aptamer‐coated hollow mesoporous silica nanoparticles.